Novel Locus Required for Expression of High-Level Macrolide-Lincosamide-Streptogramin B Resistance in Staphylococcus aureus
AUTOR(ES)
Martin, P. K.
FONTE
American Society for Microbiology
RESUMO
The yycF1(Ts) mutation in Staphylococcus aureus conferred hypersensitivity to macrolide-lincosamide-streptogramin B (MLSB) antibiotics on strains either containing or lacking ermB. The overexpression of the S. aureus Ssa protein restored the yycF1 mutant to wild-type levels of susceptibility. Inactivation of ssa in an unmutagenized strain dramatically reduced ermB-based resistance. Conditional loss of function or expression of ssa in the yycF1 mutant is proposed to result in the observed hypersensitivity to MLSB antibiotics.
ACESSO AO ARTIGO
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=139611Documentos Relacionados
- Nomenclature for Macrolide and Macrolide-Lincosamide-Streptogramin B Resistance Determinants
- Heterogeneity of Macrolide-Lincosamide-Streptogramin B Resistance Phenotypes in Enterococci
- Nucleotide sequence of ermA, a macrolide-lincosamide-streptogramin B determinant in Staphylococcus aureus.
- Naturally occurring macrolide-lincosamide-streptogramin B resistance in Bacillus licheniformis.
- Regulation of the macrolide-lincosamide-streptogramin B resistance gene ermD.
